Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial

被引：0
|
作者：
Wang, Y. -Y. [1 ]
Gu, Z. -T. [1 ]
Bao, F. -C. [1 ]
Mao, T. [1 ]
Ji, C. -Y. [1 ]
Fang, W. -T. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Aumolertinib; Neoadjuvant targeted therapy; EGFR-mutated NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP07.05-17
引用
收藏
页码：S565 / S565
页数：1
相关论文
共 50 条
  • [1] Aumolertinib as adjuvant therapy in postoperative EGFR-mutated non-small cell lung cancer
    Zhang, Q.
    He, C.
    He, T.
    Wang, Y.
    Lv, W.
    Hu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S73 - S73
  • [2] Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
    Shepherd, Annemarie F.
    Preeshagul, Isabel R.
    Shaverdian, Narek
    Wu, Abraham J.
    Gelblum, Daphna Y.
    Gomez, Daniel R.
    Rimner, Andreas
    Simone, Charles B., II
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (23)
  • [3] Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer
    Aredo, Jacqueline V.
    Urisman, Anatoly
    Gubens, Matthew A.
    Mulvey, Claire
    Allen, Greg M.
    Rotow, Julia K.
    Kerr, Daniel Lucas
    Chakrabarti, Turja
    Bacaltos, Bianca
    Gee, Megan
    Jones, Kirk
    Aisner, Dara L.
    Patil, Tejas
    Schenk, Erin Lynn
    Bivona, Trever G.
    Riess, Jonathan W.
    Coleman, Melissa
    Kratz, Johannes Ruediger
    Jablons, David
    Blakely, Collin M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions
    Ma, H.
    Huang, H.
    Feng, Y.
    Chen, S.
    Li, G.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S559 - S560
  • [5] Aumolertinib as Neoadjuvant Therapy for EGFR M plus NSCLC: A Subcohort Analysis of PURPOSE Trial Data Updated
    Wang, Y. Y.
    Gu, Z. T.
    Bao, F. C.
    Mao, T.
    Ji, C. Y.
    Wang, J.
    Cai, Y. R.
    Li, B.
    Fang, W. T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S571 - S571
  • [6] Treatment strategy of EGFR-mutated non-small cell lung cancer
    Tanaka, Fumihiro
    Yoneda, Kazue
    Takenaka, Masaru
    Kuroda, Koji
    JOURNAL OF THORACIC DISEASE, 2022, 14 (03) : 602 - 606
  • [7] Emerging drugs for EGFR-mutated non-small cell lung cancer
    Sukrithan, Vineeth
    Deng, Lei
    Barbar, Alexander
    Cheng, Haiying
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (01) : 5 - 16
  • [8] How to Treat EGFR-Mutated Non-Small Cell Lung Cancer
    Belani, Neel
    Liang, Katherine
    Fradley, Michael
    Judd, Julia
    Borghaei, Hossein
    JACC: CARDIOONCOLOGY, 2023, 5 (04): : 542 - 545
  • [9] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [10] Systemic treatment of EGFR-mutated non-small cell lung cancer
    Czyzykowski, Rafal L.
    Wrona, Ewa K.
    Talajko, Agata
    Hasinska, Aleksandra M.
    Potemski, Piotr J.
    ONCOLOGY IN CLINICAL PRACTICE, 2024,
12345